This site provides INTERCEPT product information for International audiences Select your region
Reduced Bacterial Risk with INTERCEPT
National haemovigilance data from France and Switzerland has demonstrated the prevention of septic cases with INTERCEPT™-treated platelets. In France (ANSM) and Switzerland (Swissmedic), haemovigilance reporting, including septic transfusion reactions and fatalities associated with platelet transfusions, is required by national regulatory authorities. Since the introduction of INTERCEPT in Swiss and French centres, no septic incidents have been associated with INTERCEPT-treated platelets. In contrast, such events continue to be reported in recipients of untreated platelets.